Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation

Chong-Kin Liam, Mau-Ern Poh, Yong-Sheng Liam


Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the treatment of choice for patients with advanced stage non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations (1,2). Before osimertinib, a third-generation EGFR-TKI, is recommended as the preferred agent in the first-line treatment in these patients, earlier generation TKIs such as erlotinib, gefitinib and afatinib, were the drug options available.